Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Cancer news

Show

From To
Gay men 'should get anti-cancer jab'

The HPV vaccine should be given to men who have sex with men, according to the government's experts. It is is already given to schoolgirls in the UK, but there have been calls for the vaccination programme to be extended. The Joint Committee on Vaccination and Immunisation now recommends offering the jab at sexual health clinics to men who have sex with men, aged between 16 and 40.

Published
12 November 2014
From
BBC News
Tobacco use associated with increased risk of oral HPV-16 infection

Study participants who reported tobacco use or had higher levels of biomarkers of tobacco exposure had a higher prevalence of the sexually transmitted infection, oral human papillomavirus type 16, according to a study in the Oct. 8 JAMA, a theme issue on infectious disease. HPV-16 is the most common cancer-causing variety of HPV.

Published
08 October 2014
From
Eurekalert
Population-based evidence for the preventative efficacy of quadrivalent HPV in Australia

A recently published study claims to provide the first whole population analysis of the impact on genital warts of a national HPV vaccination programme – and this may be the best predictor of the longer-term, and more important, cancer prevention benefits to be seen in future years. The findings show a decline of 89.9% in admissions involving warts from 2006/7 to 2010/11 for girls aged 12-17 yrs, a decline of 72.7% for women aged 18-26, and a decline of 38% for men aged 18-14 (the indirect effect of female vaccination).

Published
01 October 2014
From
BMJ Group blogs
Leading parliamentarians support HPV vaccination for boys

Six leading parliamentarians have today declared their support for vaccinating boys against HPV infection. Their joint statement said: "In our view, all adolescent boys should be offered the vaccine."

Published
09 September 2014
From
HPV Action
With advances in HIV care, survivors face other disease risks

As effective treatments for HIV become more widely available in low-income and middle-income countries, there's an urgent need to assess and manage health risks in the growing number of people living with HIV. An update on non-communicable diseases among HIV-positive populations in low-income and middle-income countries appears as a supplement to in JAIDS: Journal of Acquired Immune Deficiency Syndromes. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

Published
14 August 2014
From
Eurekalert Medicine & Health
Advice on Best ART Regimen for Patients Taking Cancer Therapy

Because no clinical trials address the question and published data are insufficient to support guidelines, the optimal antiretroviral therapy (ART) regimen for patients undergoing cancer chemotherapy remains unknown. But experts from Houston’s M.D. Anderson Cancer Center offer suggestions to help clinicians individualize therapy for each patient.

Published
25 June 2014
From
International AIDS Society
Gardasil cleared for anal cancer prevention in EU

The European Commission has approved a new indication for Sanofi Pasteur MSD's human papillomavirus (HPV) vaccine Gardasil, giving the nod for it to be used in the prevention of anal cancer.

Published
19 June 2014
From
PMLive
Prostate cancer ‘could be a sexually transmitted disease’, scientists say

Research by the University of California found a sex infection called trichomoniasis supported cancer growth when a team of scientists tested human prostate cells in a laboratory.

Published
20 May 2014
From
The Independent
Big Pharma, my cancer patient and me

Compassionate access schemes for these incredibly expensive drugs might facilitate access for selected patients but they are not truly compassionate in the way that the average person understands. If government subsidy looks unlikely, access schemes are retired, sometimes abruptly.

Published
02 May 2014
From
The Guardian
Gardasil®: CHMP Grants Positive Opinion for New Indication, for the Prevention of Anal Cancers and Anal Precancerous Lesions, in the European Union

The efficacy of Gardasil® against anal disease - anal intraepithelial neoplasia (AIN) and anal cancer - was evaluated in a population of 598 men who have sex with men between 16 and 26 years of age naïve to HPV types 6, 11, 16 and 18. The efficacy of Gardasil® in reducing the incidence of anal precancerous lesions grades 2/3 (AIN 2/3) related to vaccine HPV types 6, 11, 16 & 18 was 74.9%. Median duration of follow-up was 2.15 years.

Published
30 April 2014
From
Sanofi Pasteur press release
← First12345...16Next →

Filter by country